Ancient History vs. Modern Market Strategy: Botanical shift: Ashwagandha

The regulatory landscape for botanical ingredients is undergoing a significant transformation. Traditional use, once considered a strong indicator of safety, is no longer sufficient as a stand-alone justification for modern dietary supplements. Modern regulatory aspirations for supplements alter traditional context through concentrated extracts, product specific evidence, and target consumer groups.

Ashwagandha (Withania somnifera) represents a particularly relevant case study. This article outlines the evolving regulatory perspective and provides a structured, market-oriented strategy for companies seeking to develop compliant and defensible Ashwagandha-based products.

For decades, Ashwagandha has been positioned as a tradition-backed botanical with a long history of use in Ayurvedic practice. But the global regulatory expectations around botanicals is now changing. Despite its longstanding use in traditional medicine, it is now subject to growing regulatory scrutiny across multiple markets, highlighting inconsistencies in classification, permitted uses and safety expectations.

Ashwagandha demonstrates a highly fragmented global regulatory landscape, with significant variations in classification and market access.

In the United States and Canada, it remains commercially viable under dietary supplement or natural health product frameworks, with full manufacturer responsibility for safety substantiation.

Across Europe, authorities converging on a precautionary approach despite the absence of harmonised EU rules. At EU level, a full EFSA safety evaluation is expected to start and it could ultimately result in EU-wide restrictions or a ban. In parallel, the United Kingdom is conducting its own assessment: the Food Standards Agency is now reviewing data to determine whether a safe level of use can be established, with regulatory outcomes still pending. At national level, several countries, including the Netherlands and Germany, allow continued market presence but have issued precautionary warnings to consumers. By contrast, Denmark has taken a more stringent position, introducing a market prohibition following a national risk assessment that could not establish a safe intake level.

In Asia, many countries position Ashwagandha under traditional medicine frameworks rather than mainstream foods, while China and Japan largely restrict its use in food products.

In Latin America, several countries do not recognise it as a permitted dietary supplement ingredient, requiring pharmaceutical or case-by-case approval routes.

Similarly, Australia and New Zealand classify it within therapeutic or natural medicine pathways rather than food.

The industry is moving from storytelling to strict substantiation. Success depends on analytical fingerprinting, controlled withanolides, and tight Withaferin-A limits. Companies must proactively audit supply chains and implement market-specific label warnings.  

For botanicals, the future of safety strategy is not: “This herb has been trusted for centuries.” It is: “This specific root extract, at this dose, with this safety profile, for this claim, in this market, is compliant and defensible.”